GenNext Technologies announced a partnership with Kiko Tech Co., to provide Flash Oxidation Protein Footprinting Systems to the Japanese life science research market.

Under an agreement between the parties, Kiko Tech has been appointed the sole distributor for the GenNext product portfolio for Japan. Together, GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation Protein Footprinting Systems.

Kiko Tech is a premier distributor of state-of-the-art instruments and reagents for molecular diagnostics, proteomics, applied testing, pharmaceutical, and academic research since its establishment in 1974. The Kiko Tech team is excited about the opportunity to introduce the Japanese scientific community to the novel Fox based approach to Hydroxyl Radical Protein Footprinting (HRPF).

GenNext introduced Fox-Based HRPF to the market as a disruptive, intrinsically scalable approach to protein Higher Order Structure (HOS) analysis to increase the effectiveness and minimize adverse drug reactions of biopharmaceuticals. This protein footprinting method, originally demonstrated in a 2021 Journal of the American Society of Mass Spectrometry paper, is experiencing rapid adoption in North America and Europe by leading biopharmaceutical companies.

"The GenNext team is very pleased to collaborate with Kiko Tech to introduce our products to Japan as part of our global expansion program," said Scot R. Weinberger, CEO and Founder of GenNext. He continued, "We anticipate that Japanese biopharmaceutical researchers will be receptive to and adopt HRPF as a new standard to elucidate HOS, and we have found the perfect partner in Kiko Tech who are already active in this area."

"Kiko Tech is excited to bring GenNext products to the Japanese life science community," said Shigenobu Fukushima, General Manager of Kiko Tech. "GenNext’s products move HOS beyond the limitations inherent in current techniques, enabling our customers to discover and develop biopharmaceuticals faster and with higher quality."